Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Phase II topline results are expected in late 2024, with analysts anticipating data that could position MariTide competitively in the rapidly growing obesity treatment market. Some analysts ...

Phase II topline results are expected in late 2024, with analysts anticipating data that could position MariTide competitively in the rapidly growing obesity treatment market. Some analysts project ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 products by mimicking a hormone in the body that provides a satiated feeling, ...

It looks as if the volatility of the obesity market has impacted the ticker, providing an opportunity for investors to possibly add to their position. I intend to review some recent headlines and ...

The rise in popularity of anti-obesity medications (AOMs), such as ... the company include the deregulation of the export wheat market, the introduction of genetically modified crops and the ...

The result for now is that Novo Nordisk is no longer the most valuable company in Europe, and anti-obesity specialists have entered bear market territory. Sachin Jain from Bank of America points ...

A group of 58 researchers is calling for a new, better way to measure obesity. The global team’s recommendations were published in The Lancet Diabetes & Endocrinology on Jan. 14. Body mass index ...

LONDON – Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and adding broader measurements such as heart health. The ...